<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> has been associated with an increased <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk, which can be modified by specific <z:chebi fb="0" ids="35526">hypoglycemic drugs</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>In particular, <z:chebi fb="0" ids="6801">metformin</z:chebi>, the most frequently prescribed <z:chebi fb="0" ids="3095">biguanide</z:chebi>, is now considered a <z:chebi fb="1" ids="50267">protective agent</z:chebi> against <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidence and mortality in Type 2 diabetic patients </plain></SENT>
<SENT sid="2" pm="."><plain>AIMS: To review the potential associations between <z:chebi fb="0" ids="6801">metformin</z:chebi> use and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidence and mortality and the possible biological links implicated in these associations </plain></SENT>
<SENT sid="3" pm="."><plain>MATERIALS AND METHODS: We searched English-language original investigations published through September 2011 </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:chebi fb="0" ids="6801">Metformin</z:chebi> could block the mitogenic effects of insulin, but this effect does not entirely explain the reduction in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidence </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> also plays a direct inhibition of <z:e sem="disease" ids="C1516170" disease_type="Neoplastic Process" abbrv="">cancer cell growth</z:e> via the inhibitory effects of <z:chebi fb="47" ids="16027,28971">AMP</z:chebi>-activated protein kinase on the mTOR pathway, which regulates cell growth and proliferation </plain></SENT>
<SENT sid="6" pm="."><plain>Accordingly, many epidemiological studies have shown that <z:chebi fb="0" ids="6801">metformin</z:chebi> use is associated with a lower <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidence and mortality through a dose-response relationship, with greater exposure being associated with stronger risk reduction </plain></SENT>
<SENT sid="7" pm="."><plain>Randomized clinical trials testing the effects of <z:chebi fb="0" ids="6801">metformin</z:chebi> on both recurrence and survival in early-stage <z:hpo ids='HP_0003002'>breast cancer</z:hpo> are on-going; these trials are based on pilot studies demonstrating an adjuvant effect of this drug in <z:hpo ids='HP_0003002'>breast cancer</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="6801">Metformin</z:chebi> is an inexpensive and safe drug, that may modify the increased <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk of Type 2 diabetic patients </plain></SENT>
<SENT sid="9" pm="."><plain>On-going clinical trials will show whether this drug can enhance the effect of chemotherapy in the treatment of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>